OUTLOOK THERAPEUTICS INC (OTLK)
US69012T3059 - Common Stock
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first...
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J.,...
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement, for upfront gross proceeds of approximately $60 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting placement agent fees and offering expenses. Outlook Therapeutics has the potential to receive additional gross proceeds of up to $99 million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses.
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to...
7 of the Best Speculative Stocks You Can Snag for Less Than $1
Although speculative stocks under $1 are by their very nature extremely risky, these ideas might have enough to go the distance.
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.
Outlook Therapeutics stock climbs 13% amid Chardan upgrade (NASDAQ:OTLK)
Shares of Outlook Therapeutics (OTLK) climbed 13% after Chardan upgraded the stock to buy, citing the company’s recent private placement and the full cash exerc
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
NORSE EIGHT underway with first subject dosed and additional clinical sites beginning enrollment Continue to expect planned resubmission of the ONS-5010...
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Biologics...
Outlook stock rallies on private placement, FDA study agreement (NASDAQ:OTLK)
Outlook Therapeutics (OTLK) stock rallied after it announced plans to privately place up to $172M of its securities and issued an update on key study for its eye drug ONS-5010.
OTLK FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) of a class action securities...
OTLK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
OTLK IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
OTLK DEADLINE ALERT: ROSEN, A LEADING AND RANKED FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
OTLK DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ:...
OTLK DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK)
OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Outlook Therapeutics, Inc. ("Outlook"...
OTLK Stock Earnings: Outlook Therapeutics Reported Results for Q4 2023
Outlook Therapeutics just reported results for the fourth quarter of 2023.
OTLK Stock Earnings: Outlook Therapeutics Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Outlook Therapeutics (NASDAQ:OTLK) just reported results for the fourth quarter...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) of a class action securities...